Managing risk when considering the use of atypical antipsychotics for elderly patients with dementia-related psychosis

Journal of Psychiatric Practice

Volumn 13, Issue 3, 2007, Pages 143-152

  Recupero, Patricia R ^a   Rainey, Samara E ^a  

^a BUTLER HOSPITAL   (United States)

Author keywords

Antipsychotic medications; Dementia; Geriatrics; Psychopharmacology; Risk management

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGED; AGITATION; BEHAVIOR MODIFICATION; BEHAVIOR THERAPY; CLINICAL DECISION MAKING; DEMENTIA; DRUG INFORMATION; DRUG SAFETY; DRUG USE; FOOD AND DRUG ADMINISTRATION; GERIATRIC PATIENT; HUMAN; INFORMED CONSENT; MEDICAL DOCUMENTATION; PATIENT ASSESSMENT; PRACTICE GUIDELINE; PSYCHOSIS; REVIEW; RISK MANAGEMENT; TARDIVE DYSKINESIA;

AGED; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; DOCUMENTATION; DRUG MONITORING; HUMANS; INFORMED CONSENT; PRODUCT LABELING; PSYCHOTIC DISORDERS; RISK MANAGEMENT;

EID: 34249297989     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000271655.02093.49     Document Type: Review

References (33)

1. Authors' search, January 2006.
2. Berenson A. States study marketing of Lilly pill. New York Times, January 20, 2007 , accessed online January 22, 2007 (Available at select.nytimes.com/ gst/abstract.html?res=F70915F835540C738EDDA80894DF404482).
3. Harris Interactive. U.S. adults ambivalent about the risks and benefits of off-label prescription drug use. Harris Poll/Wall Street Journal Online Health-Care Poll; 5(21):1-5, December 7, 2006, accessed online January 22, 2007 (Available at www.harrisinteractive.com/news/allnewsbydate.asp?NewsID=1126).
4. Chan W, Lam LC, Choy CN, et al. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatric Psychiatry 2001;16:1156-62.
5. De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatric Psychiatry 2004;19: 115-26.
6. Fujikawa T, Takahashi T, Kinoshita A, et al. Quetiapine treatment for behavioral and psychological symptoms in patients with senile dementia of Alzheimer type. Neuropsychobiology 2004;49:201-4.
7. Brodaty H, Ames D, Snowdon J, et al. A Randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003;64:134-43.
8. Liperoti R, Pedone C, Lapane KL, et al. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Int Med 2005;165:2677-82.
9. US Food and Drug Administration: 2004 Safety Alert: Zyprexa (olanzapine) [On-line]. www.fda.gov/medwatch/SAFETY/2004/zyprexa.htm. Accessed February 2, 2006.
10. Shekelle P, Maglione M, Bagley S, et al. Comparative effectiveness of off-label use of atypical antipsychotics. Comparative Effectiveness Review No. 6 (Prepared by Southern California/RAND Evidence-based Practice Center under Contract No. 290-02-0003.) Rockville, MD: Agency for Healthcare Research and Quality. January 2007, accessed online January 22, 2007. (Available at www.effective-healthcare.ahrq.gov/reports/final.cfm).
11. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43.
12. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-38.
13. Ballard C, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006;1:CD003476.
14. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006;14:191-210.
15. Carson S, McDonagh MS, Peterson K. A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. J Am Geriatrics Soc 2006;54:354-61.
16. US Food and Drug Administration: FDA Public Health Advisory: Deaths with antipsychotics in elderly patients with behavioral disturbances, April 11, 2005, accessed January 30, 2006. (Available at www.fda.gov/cder/drug/advisory/ antipsychotics.htm).
17. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353:2335-41.
18. Sink KM, Holden, KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia. JAMA 2005;293:596-608.
19. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Washington, DC: American Psychiatric Press; 1997.
20. Rabins PV: Guideline watch: Practice guideline for the treatment of patients With Alzheimer's disease and other dementias of late life. Washington, DC, American Psychiatric Association; 2006, accessed April 20, 2007 (available online at http://www.psych.org/psych_pract/treatg/pg/prac_guide.cfm).
21. Alexopoulos GS, Jeste DV, Chung H, et al. The expert consensus guideline series: Treatment of dementia and its behavioral disturbances. Postgrad Med Spec Rep 2005 (January):1-101.
22. Gwyther LP, Steffens DC. Agitation and suspiciousness. In: Blazer DG, Steffens DC, Busse EW, eds. The American Psychiatric Publishing textbook of geriatric psychiatry, third edition. Washington, DC: American Psychiatric Publishing; 2004:377-83.
23. Alexopoulos GS, Jeste DV, Chung H, et al. Treatment of dementia and agitation: A guide for families and caregivers. Postgrad Med Spec Rep 2005 (January):101-8.
24. Katona CLE. Psychotropics and drug interactions in the elderly patient. Int J Geriatric Psychiatry 2001;16:S86-S90.
25. Fabbrini G, Barbanti P, Aurilia C. Tardive dyskinesias in the elderly. Int J Geriatric Psychiatry 2001;16:S19-S23.
26. Jeste DV, Dolder CR, Nayak GV, et al. Atypical antipsychotics in elderly patients with dementia or schizophrenia: Review of recent literature. Harv Rev Psychiatry 2005;13:340-51.
27. Lee PE, Sykora K, Gill SS. Antipsychotic medications and drug-induced movement disorders other than Parkinsonism: A population-based cohort study in older adults. J Am Geriatr Soc 2005;53:1374-9.
28. Mulsant BH, Pollock BG. Psychopharmacology. In: Blazer DG, Steffens DC, Busse EW, eds. The American Psychiatric Publishing textbook of geriatric psychiatry, third edition. Washington, DC: American Psychiatric Publishing; 2004:387-411.
29. Lee PE, Gill SS, Freedman M, et al. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: Systematic review. BMJ 2004;329:75.
30. Kelly PA, Carney EA. Managing dementia: Risks of using vs. not using atypical antipsychotics. Curr Psychiatry 2005;4:14-28.
31. Olmstead v. L.C., 527 U.S. 581 (1999)
32. Kramer SI, McCall WV. Off-label prescribing: 7 steps for safer, more effective treatment. Curr Psychiatry 2006;5:15-6, 21-2, 26-8.
33. Heres S, Davis J, Maino K, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006;163:185-94.